Wird geladen...

Economic evaluation of rituximab plus cyclophosphamide, vincristine and prednisolone for advanced follicular lymphoma

The addition of rituximab to cyclophosphamide, vincristine and prednisolone (CVP) for advanced follicular lymphoma increases median time to progression by 17 months. A US societal cost-effectiveness of R-CVP versus CVP is estimated for a representative 50-year-old patient. Progression-free survival...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Hornberger, John, Reyes, Carolina, Lubeck, Deborah, Valente, Nancy
Format: Artigo
Sprache:Inglês
Veröffentlicht: Informa Healthcare 2008
Schlagworte:
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC2430747/
https://ncbi.nlm.nih.gov/pubmed/18231908
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/10428190701769665
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!